ArticleFrontiers in aging neuroscience2024
Dynamic changes and prognostic value of glutathione S-transferase alpha in mild cognitive impairment and Alzheimer's disease.
Article in Frontiers in aging neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Resources and applications of public biomedical data.Frontiers in bioinformatics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Glutathione S-transferase alpha (GSTα) is an important antioxidant enzyme closely associated with the onset and progression of neurodegenerative diseases. The alterations in GSTα protein levels associated with Alzheimer's disease and their impact on cognitive abilities remain unclear. Thus, investigating the fluctuations of GSTα protein levels in mild cognitive impairment (MCI) and Alzheimer's disease (AD) is essential. Methods: DATA were enrolled from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, and we studied healthy individuals (as controls, a total of 54), patients with mild cognitive impairment (345), and patients with Alzheimer's disease (96) A one-year follow-up was conducted to collect data on the dynamic changes of GSTα protein levels in plasma and primary information data, and to analyze the correlation between the changes in GSTα protein levels before and after the follow-up and cognitive function and its predictive value. Results: Plasma GSTα protein levels were significantly lower in the AD group than in the CN group (0.94 vs1.05, Conclusion: The findings of the study indicated notable differences in GSTα protein levels among patients with MCI and those with AD after a one-year follow-up period. Furthermore, a positive correlation was observed between changes in GST αprotein levels and the decline in both baseline and cognitive function. This suggests that GSTα protein could potentially act as a biomarker for both MCI and AD, offering fresh insights for early detection and intervention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.